8-K: TG Therapeutics Announces Preliminary Q4 and Full Year 2024 Revenue, Outlines 2025 Milestones

TG Therapeutics reports strong preliminary revenue for BRIUMVI in 2024 and sets ambitious targets for 2025, including expansion into subcutaneous administration and other autoimmune diseases.

Summary

• TG Therapeutics announced preliminary unaudited U.S. net product revenue for BRIUMVI for Q4 2024 at $103.6 million.
• Full year 2024 BRIUMVI U.S. net product revenue reached $310 million.
• The company is targeting total global revenue of approximately $540 million for 2025, including $525 million from BRIUMVI U.S. net product revenue.
• TG Therapeutics anticipates full year 2025 operating expenses of approximately $300 million.
• Key milestones for 2025 include commencing a pivotal program for subcutaneous BRIUMVI and pivotal programs to optimize intravenous BRIUMVI.
• The company also plans to enroll participants in trials evaluating BRIUMVI in other autoimmune diseases and a Phase 1 trial of azer-cel in progressive MS.
• TG Therapeutics ended 2024 with a cash position of approximately $310 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and ambitious targets. The company is expanding its product pipeline and has a solid cash position. However, risks related to commercialization and regulatory approvals exist.

Positives

• BRIUMVI sales exceeded initial expectations in 2024.
• The company has a strong cash position of approximately $310 million.
• TG Therapeutics is expanding BRIUMVI's administration options with a subcutaneous formulation.
• The company is exploring BRIUMVI's potential in other autoimmune diseases.

Negatives

• The preliminary financial results are unaudited and subject to change.
• The company faces risks related to commercialization, regulatory approvals, and manufacturing.

Risks

• The company's ability to establish and maintain a commercial infrastructure for BRIUMVI is a risk.
• Failure to obtain and maintain payor coverage could impact revenue.
• Reliance on third parties for manufacturing, distribution, and supply poses a risk.
• Regulatory challenges to marketing approval in jurisdictions outside the U.S. exist.
• Clinical experience in the post-marketing setting may differ from controlled clinical trials.
• Subcutaneous BRIUMVI may not exhibit favorable safety, efficacy, or pharmacokinetic properties.
• The safety or tolerability profile of BRIUMVI may differ in other autoimmune disorders.
• Delays in initiating clinical trials for azer-cel in non-oncology indications are possible.

Future Outlook

TG Therapeutics anticipates continued growth for BRIUMVI and aims to expand its use through subcutaneous administration and into other autoimmune diseases. The company has set ambitious revenue targets for 2025 and plans to advance its development pipeline.

Management Comments

• Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, '2024 was a great year for TG, and we are excited to share preliminary fourth quarter and year end U.S. BRIUMVI net product revenue which far exceeded our initial expectations.'

Industry Context

The announcement comes during the J.P. Morgan Healthcare Conference, a key event for pharmaceutical companies to share updates and guidance. TG Therapeutics is positioning BRIUMVI as a best-in-class treatment for RMS and is exploring its potential in other autoimmune diseases, aligning with the industry trend of expanding drug indications.

Comparison to Industry Standards

• BRIUMVI competes with other anti-CD20 therapies like Ocrevus (Roche) in the RMS market.
• The targeted $540 million global revenue for 2025 would represent a significant increase, but still trails behind established players like Roche.
• The development of a subcutaneous formulation aims to improve patient convenience, similar to trends seen with other injectable MS therapies like Kesimpta (Novartis).

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth and future prospects.
• Patients: Potential for improved treatment options with subcutaneous BRIUMVI and expansion into other autoimmune diseases.
• Employees: Positive impact due to company growth and expansion.

Next Steps

• Commence pivotal program of subcutaneous BRIUMVI.
• Commence pivotal programs to consolidate the Day 1 and Day 15 dose of BRIUMVI, and to evaluate 30 minute BRIUMVI maintenance infusions.
• Enroll participants into the ongoing trial evaluating BRIUMVI in autoimmune diseases outside of Multiple Sclerosis (MS).
• Enroll participants into the Phase 1 azer-cel trial in autoimmune disease, beginning with primary progressive MS.
• Present updated data at major medical conferences throughout the year.

Key Dates